Zoledronic acid for treatment of Paget's disease of bone

• VAN STAA TP, SELBY P, LEUFKENS HGM, LYLES K, SPRAFKA JM, COOPER C: Incidence and natural history of Paget's disease of bone in England and Wales. J. Bone Miner. Res. (2002) 17(3):465-471.
   PubMed Web of Science ®Google Scholar
• LANGSTON AL, CAMPBELL MK, FRASER WD, MACLENNAN G, SELBY P, RALSTON SH; FOR THE PRISM TRIAL GROUP: Clinical determinants of quality of life in Paget's disease of bone. Calcif. Tissue Int. (2007) 80(1):1-9.
   PubMed Web of Science ®Google Scholar
• BEYENS G, DAROSZEWSKA A, DE FREITAS F et al.: Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone. J. Bone Miner. Res. (2007) 22(7):1062-1071.
   PubMed Web of Science ®Google Scholar
• BASLE MF, FOURNIER JG, ROZENBLATT S, REBEL A, BOUTEILLE M: Measles virus RNA detected in Paget's disease bone tissue by in situ hybridization. J. Gen. Virol. (1986) 67(Part 5):907-913.
   PubMed Web of Science ®Google Scholar
• BARKER DJ, CLOUGH PW, GUYER PB, GARDNER MJ: Paget's disease of bone in 14 British towns. BMJ (1977) 1(6070):1181-1183.
   PubMedGoogle Scholar
• COOPER C, SCHAFHEUTLE K, DENNISON E, KELLINGRAY S, GUYER P, BARKER D: The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J. Bone Miner. Res. (1999) 14(2):192-197.
   PubMed Web of Science ®Google Scholar
• DOYLE T, GUNN J, ANDERSON G, CUNDY T: Paget's disease in New Zealand: evidence for declining prevalence. Bone (2002) 31(5):616-619.
   PubMed Web of Science ®Google Scholar
• CUNDY HR, GAMBLE G, WATTIE D, RUTLAND M, CUNDY T: Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif. Tissue Int. (2004) 75(5):358-364.
   PubMed Web of Science ®Google Scholar
• RAPADO A, JIMENEZ J, MORALES A, CARBONELL J, DEL PINO J: Patterns of diagnosis of Paget's disease in Spain. J. Bone Miner. Res. (1999) 14(Suppl. 2):S96-S98.
   PubMed Web of Science ®Google Scholar
• GENNARI L, DI STEFANO M, MERLOTTI D et al.: Prevalence of Paget's disease of bone in Italy. J. Bone Miner. Res. (2005) 20(10):1845-1850.
   PubMed Web of Science ®Google Scholar
• RALSTON SH: Bisphosphonates in the management of Paget's disease. J. Bone Miner. Res. (2007) 22(7):1106-1107.
   Google Scholar
• MALDAGUE B, MALGHEM J: Dynamic radiologic patterns of Paget's disease of bone. Clin. Orthop. (1987) 217:126-151.
   Google Scholar
• DEVOGELAER JP: Modern therapy for Paget's disease of bone. Focus on bisphosphonates. Treat. Endocrinol. (2002) 1(4):241-257.
   PubMedGoogle Scholar
• GREEN JR, ROGERS MJ: Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev. Res. (2002) 55:210-224.
   Web of Science ®Google Scholar
• NANCOLLAS GH, TANG R, PHIPPS RJ et al.: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2006) 38(5):617-627.
   PubMed Web of Science ®Google Scholar
• VIERECK V, EMONS G, LAUCK V et al.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Com. (2002) 291(3):680-686.
   PubMed Web of Science ®Google Scholar
• ARDEN-CORDONE M, SIRIS ES, LYLES KW et al.: Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif. Tissue Int. (1997) 60(5):415-418.
   PubMed Web of Science ®Google Scholar
• BUCKLER H, FRASER W, HOSKING D et al.: Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone (1999) 24(5)(Suppl. 1):S81-S85.
   PubMed Web of Science ®Google Scholar
• REID IR, MILLER P, LYLES K et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. (2005) 353(9):898-908.
   PubMed Web of Science ®Google Scholar
• PATEL S, STONE MD, COUPLAND C, HOSKING DJ: Determinants of remission of Paget's disease of bone. J. Bone Miner. Res. (1993) 8(12):1467-1473.
   PubMed Web of Science ®Google Scholar
• DEVOGELAER JP, BROWN JP, BURKHARDT P et al.: Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. (2007) 18(9):1211-1218.
   PubMed Web of Science ®Google Scholar
• BLACK DM, DELMAS PD, EASTELL R et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. (2007) 356(18):1809-1822.
   PubMed Web of Science ®Google Scholar
• HOSKING D, LYLES K, BROWN JP et al.: Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J. Bone Miner. Res. (2007) 22(1):142-148.
   PubMed Web of Science ®Google Scholar
• MERLOTTI D, GENNARI L, MARTINI G et al.: Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J. Bone Miner. Res. 22(10):1510-1517.
   Google Scholar
• LECOMTE P, DEVOGELAER JP, KAUFMAN JM, GOEMAERE S, GEUSENS P, ENGBERSEN A: Cost-effectiveness analysis of Aclasta in Paget's disease of bone in Belgium. Value Health (2005) 8(6):A73.
   Google Scholar
• HEWITT RE, LISSINA A, GREEN AE, SLAY ES, PRICE DA, SEWELL AK: The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. (2005) 139:101-111.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ GS, FINE PL, STACK JI et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. (2003) 64:281-289.
   PubMed Web of Science ®Google Scholar
• ALVAREZ L, PERIS P, GUANABENS N et al.: Long-term biochemical response after bisphosphonate thrapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology (2004) 43(7):869-874.
   PubMed Web of Science ®Google Scholar
• WOITGE HW, OBERWITTLER H, HEICHEL S et al.: Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin. Chem. (2000) 46(5):684-690.
   PubMed Web of Science ®Google Scholar
• REID IR, DAVIDSON JS, WATTIE D et al.: Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone (2004) 35(1):224-230.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, LEWIECKI EM, COHEN SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354(8):821-831.
   PubMed Web of Science ®Google Scholar

Website

• http://www.emea.eu.int EUROPEAN MEDICINES AGENCY; EMEA/H/C/595 2005: Rapport EuropÉen Public d'Évaluation (EPAR) du comitÉ des mÉdicaments À usage humain. ACLASTA. (Accessed 13 September 2007).
   Google Scholar